Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DACAMI: Dapagliflozin in Anterior MI
NCT05424315Phase 3Completed
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Anterior ST-Elevation Myocardial Infarction comparing Dapagliflozin Group with Placebo Group (2 arms). Primary endpoints: Change in N-terminal pro-Brain Natriuretic Peptide levels at 12 weeks, Change in Left Ventricular Ejection Fraction at 12 weeks and 2 more. Started Oct 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Acute Anterior ST-Elevation Myocardial Infarction
Beyond the preview
Go deeper on NCT05424315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05424315.